ALK delivers 15% organic revenue growth with an operating profit (EBIT) margin of 27% in Q3
ALK delivered 15% organic revenue growth in Q3, driven by tablet sales, which grew by 35%, with solid growth across sales regions. Operating profit increased by 9% with an EBIT margin of 27% in the quarter and 28% for the first nine months. The full-year outlook, upgraded on 7 October 2026, has been confirmed.
Performance highlights (Q3)
Comparative figures for Q3 2025 are shown in brackets. Growth rates are stated in local currencies (l.c.), unless otherwise indicated.
Financial highlights
| Growth | Growth | ||||||||||||
| In DKKm | Q3 2026 | l.c. | r.c. | 9M 2026 | l.c. | r.c. | |||||||
| Revenue | 1,764 | 15% | 15% | 5,330 | 17% | 16% | |||||||
| EBIT | 469 | 9% | 11% | 1,484 | 16% | 17% | |||||||
| EBIT margin – % | 27% | 28% | |||||||||||
| l.c.: local currency; r.c.: reported currency | |||||||||||||
Allergy+ strategy highlights
2026 full-year outlook confirmed
The full-year financial outlook was upgraded on 7 October 2026 (reference is made to Company Release 16/2026), reflecting a strong growth momentum in tablet sales across regions. This outlook has been confirmed.
Commenting on the Q3 results, CEO Peter Halling said: “ALK’s 35% tablet growth in Q3 reflects the strength of our strategy, and paediatric use is increasingly contributing to the growth. We are very pleased that the phase 3 trial with ACARIZAX® in China met its primary objective opening up a new important opportunity, and the expanded partnership with Catalent strengthens our long-term tablet supply. Together with the upgraded outlook, this reinforces our confidence in our ability to reach more patients with evidence-based allergy and anaphylaxis solutions."
Hørsholm, 17 November 2026
ALK-Abelló A/S
For further information, contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
ALK is hosting a conference call for analysts and investors today at 3.30 p.m. (CET) at which Management will review the financial results and the outlook. The conference call will be audio cast on https://ir.alk.net where the relevant presentation will be available shortly before the call begins.
To register for the conference call, please use this link and follow the registration instructions. You will receive an email from diamondpass@choruscall.com with dial-in details, including a passcode and a pin code. Please make sure to whitelist diamondpass@choruscall.com and/or check your spam filter. We advise you to register well in advance and to call in before 3.25 p.m. (CET).
Attachment